Related Experiment Videos
Novel molecular targets for systemic lupus erythematosus
Maria Marino1, Maria Rossi, Menotti Ruvo
1Biopharmaceuticals, TECNOGEN S.C.p.A., Piana di Monte Verna CE, Italy.
Current Drug Targets
|June 4, 2002
Summary
Fc receptors (FcRs) are increasingly recognized as key drivers of inflammation in autoimmune diseases like systemic lupus erythematosus (SLE), potentially surpassing the complement cascade. Targeting FcRs offers promising new therapeutic strategies for SLE and other immune disorders.
Area of Science:
- Immunology
- Autoimmunity
- Molecular Biology
Background:
- The complement cascade was long considered the primary driver of inflammation and tissue damage in autoimmune diseases.
- Recent evidence suggests Fc receptors (FcRs) play an equally or more significant role in disease pathogenesis.
- Understanding the distinct roles of complement and FcRs in immune complex interactions is crucial.
Purpose of the Study:
- To highlight the emerging importance of Fc receptors (FcRs) in autoimmune diseases, particularly Systemic Lupus Erythematosus (SLE).
- To explore FcRs as viable therapeutic targets for autoimmune conditions.
- To present evidence supporting the role of FcRs in disease initiation and progression.
Main Methods:
- Generation of mouse strains deficient in complement or Fc receptor components.
- Assessment of biological activity of soluble FcRs and anti-Fc receptor monoclonal antibodies.
- In vitro and in vivo evaluation of compounds targeting IgG/FcgammaR interactions, such as TG19320.
Main Results:
- Complement is essential for innate immunity, while Fc gamma receptors (FcγRs) are the principal mediators of inflammatory cascades initiated by antigen-antibody complexes.
- Studies using FcR-targeting agents and compounds like TG19320 demonstrate their efficacy in preclinical models of SLE.
- TG19320 effectively inhibits IgG/FcγR interaction in vitro and prevents glomerulonephritis in vivo.
Conclusions:
- Fc receptors (FcRs) are validated as critical therapeutic targets for autoimmune diseases, including SLE.
- Targeting FcRs presents a promising avenue for developing novel treatments for SLE, rheumatoid arthritis, and multiple myeloma.
- FcR-targeted therapies may also benefit conditions like acquired immunodeficiency syndrome (AIDS).